Enzo Biochem Inc (ENZ) - Total Assets
Based on the latest financial reports, Enzo Biochem Inc (ENZ) holds total assets worth $63.52 Million USD as of April 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Enzo Biochem Inc (ENZ) net assets for net asset value and shareholders' equity analysis.
Enzo Biochem Inc - Total Assets Trend (1986–2024)
This chart illustrates how Enzo Biochem Inc's total assets have evolved over time, based on quarterly financial data.
Enzo Biochem Inc - Asset Composition Analysis
Current Asset Composition (July 2024)
Enzo Biochem Inc's total assets of $63.52 Million consist of 81.7% current assets and 18.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.1% |
| Accounts Receivable | $3.99 Million | 4.7% |
| Inventory | $6.83 Million | 8.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1986–2024)
This chart illustrates how Enzo Biochem Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ENZ market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enzo Biochem Inc's current assets represent 81.7% of total assets in 2024, an increase from 74.9% in 1986.
- Cash Position: Cash and equivalents constituted 61.1% of total assets in 2024, down from 70.4% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 1986.
- Asset Diversification: The largest asset category is inventory at 8.0% of total assets.
Enzo Biochem Inc Competitors by Total Assets
Key competitors of Enzo Biochem Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Enzo Biochem Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.84 | 3.50 | 2.10 |
| Quick Ratio | 2.50 | 3.16 | 1.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $31.27 Million | $54.07 Million | $35.96 Million |
Enzo Biochem Inc - Advanced Valuation Insights
This section examines the relationship between Enzo Biochem Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | -29.6% |
| Total Assets | $85.76 Million |
| Market Capitalization | $16.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Enzo Biochem Inc's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enzo Biochem Inc's assets decreased by 29.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enzo Biochem Inc (1986–2024)
The table below shows the annual total assets of Enzo Biochem Inc from 1986 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-07-31 | $85.76 Million | -29.63% |
| 2023-07-31 | $121.88 Million | +27.15% |
| 2022-07-31 | $95.86 Million | -15.69% |
| 2021-07-31 | $113.69 Million | +1.02% |
| 2020-07-31 | $112.54 Million | +5.53% |
| 2019-07-31 | $106.64 Million | +4.90% |
| 2018-07-31 | $101.66 Million | -5.58% |
| 2017-07-31 | $107.67 Million | -3.72% |
| 2016-07-31 | $111.82 Million | +63.50% |
| 2015-07-31 | $68.39 Million | +6.18% |
| 2014-07-31 | $64.41 Million | +9.25% |
| 2013-07-31 | $58.96 Million | -14.71% |
| 2012-07-31 | $69.12 Million | -36.86% |
| 2011-07-31 | $109.47 Million | -5.01% |
| 2010-07-31 | $115.25 Million | -13.43% |
| 2009-07-31 | $133.13 Million | -13.85% |
| 2008-07-31 | $154.52 Million | -2.82% |
| 2007-07-31 | $159.00 Million | +56.62% |
| 2006-07-31 | $101.52 Million | -12.83% |
| 2005-07-31 | $116.47 Million | +5.56% |
| 2004-07-31 | $110.33 Million | -4.78% |
| 2003-07-31 | $115.88 Million | +6.03% |
| 2002-07-31 | $109.29 Million | +6.18% |
| 2001-07-31 | $102.93 Million | +11.54% |
| 2000-07-31 | $92.29 Million | +16.96% |
| 1999-07-31 | $78.90 Million | +9.28% |
| 1998-07-31 | $72.20 Million | +7.12% |
| 1997-07-31 | $67.40 Million | +7.32% |
| 1996-07-31 | $62.80 Million | -13.38% |
| 1995-07-31 | $72.50 Million | +11.54% |
| 1994-07-31 | $65.00 Million | +36.55% |
| 1993-07-31 | $47.60 Million | -4.42% |
| 1992-07-31 | $49.80 Million | +1.01% |
| 1991-07-31 | $49.30 Million | -25.86% |
| 1990-07-31 | $66.50 Million | -10.86% |
| 1989-07-31 | $74.60 Million | +6.72% |
| 1988-07-31 | $69.90 Million | -7.66% |
| 1987-07-31 | $75.70 Million | +0.53% |
| 1986-07-31 | $75.30 Million | -- |
About Enzo Biochem Inc
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development pro… Read more